Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read More
Seaport Therapeutics and Hemab Therapeutics Set for Major Public Offerings as Biotech IPO Market Gains Momentum
Seaport Therapeutics and Hemab Therapeutics are poised to join the ranks of publicly traded companies, with both biopharmaceutical firms announcing…
Read More
Eli Lilly Acquires Ajax Therapeutics for Up to $2.3 Billion in Strategic Move to Bolster Oncology Pipeline
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
Enanta Pharmaceuticals Poised to Lead Emerging RSV Therapeutics Market as Zelicapavir Advances to Phase III
Enanta Pharmaceuticals is strategically positioned to capture a significant share of the largely undeveloped market for respiratory syncytial virus (RSV)…
Read More
Ray Therapeutics Secures $125 Million Series B Funding to Accelerate Vision Restoration Pipeline
Ray Therapeutics, a biopharmaceutical company at the forefront of developing novel gene therapies for vision restoration, has successfully closed a…
Read More
Eli Lilly Expands In Vivo Gene Therapy Arsenal with $7 Billion Acquisition of Kelonia Therapeutics
Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with…
Read More
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion to Bolster Epilepsy Pipeline with Regenerative Cell Therapy
BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
Daiichi Sankyo Partners with Interna Therapeutics to Revolutionize Targeted Drug Delivery with Molecular Nano Motor Technology
Boston, MA & Tokyo, Japan – April 17, 2026 – In a significant move to enhance the precision and efficacy…
Read MoreYOU MAY HAVE MISSED
